2026.02. 12 作者 | 第一财经 林志吟 本文字数：1099，阅读时长大约2分钟 2月12日，市场传出消息称，阿斯利康前全球执行副总裁、中国区总裁王磊被提起公诉。 第一财经记者向阿斯利康中国方面求证，但未获得回应。 阿斯利康在近日发布年报中曾提及称，2025年11月，深圳检方完成审查，并对阿斯利康中国、阿斯 利康一名前执行副总裁和一名前高级员工以涉嫌非法收集个人信息及非法贸易罪名提起公诉。该名前 执行副总裁和该名前高级员工还被追加医保诈骗罪名。 2025年4月，阿斯利康中国收到深圳市公安局宝安分局出具的《移送起诉告知书》，涉嫌非法收集 个人信息。 与此同时，2025年10月，阿斯利康中国也收到深圳海关的通知，告知阿斯利康中国未缴纳的进口税 总额为人民币2400万元（约350万美元）。评估意见中提到的进口税涉及度伐利尤单抗 （Imfinzi）、替西木单抗（Imjudo）和德曲妥珠单抗（Enhertu）这些药物。同月，阿斯利康自愿 全额预付补偿款。但若阿斯利康中国被判定为非法贸易责任人，其也可能被征收前述已支付进口税金 额一至五倍的罚款。 | China Personal Information | · ...

2025年4月，阿斯利康中国收到深圳市公安局宝安分局出具的《移送起诉告知书》，涉嫌非法收集个人 信息。 与此同时，2025年10月，阿斯利康中国也收到深圳海关的通知，告知阿斯利康中国未缴纳的进口税总额 为人民币2400万元（约350万美元）。评估意见中提到的进口税涉及度伐利尤单抗（Imfinzi）、替西木 单抗（Imjudo）和德曲妥珠单抗（Enhertu）这些药物。同月，阿斯利康自愿全额预付补偿款。但若阿 斯利康中国被判定为非法贸易责任人，其也可能被征收前述已支付进口税金额一至五倍的罚款。 相关案件由深圳市中级人民法院合并审理。 | China Personal Information | · In relation to the personal information infringement allegation, in April 2025, AstraZeneca | | --- | --- | | Infringement and Illegal Trade | Investment (China) Co., Ltd. received a Notice of Transfer to the P ...

Core Insights - AstraZeneca has faced multiple allegations in China, including personal information infringement, illegal trade, and medical insurance fraud, as disclosed in its 2025 annual report [1][2] - The company has voluntarily prepaid a compensation amount of RMB 24 million (approximately USD 3.5 million) related to unpaid import taxes for specific drugs [1] - AstraZeneca's revenue in China for 2025 was USD 6.654 billion, representing a 4% year-on-year growth, contributing approximately 11% to the company's total revenue of USD 58.739 billion, which grew by 8% [4][5] Legal Developments - In October 2025, Shenzhen Customs issued a final assessment indicating AstraZeneca China owed RMB 24 million in import taxes, with potential penalties of one to five times the paid amount if found liable for illegal trade [1] - In November 2025, the Shenzhen Prosecutor's Office completed its assessment, leading to charges against AstraZeneca China and its former executives for illegal collection of personal information and illegal trade, although AstraZeneca China was not accused of profiting from the illegal activities [1][2] Management Changes - Following the investigation, AstraZeneca appointed Iskra Reic as the new Global Executive Vice President and head of International Business, while Lin Xiao became the General Manager of AstraZeneca China [3] Investment Plans - AstraZeneca announced a USD 2.5 billion investment plan in March 2025 to establish a global strategic R&D center in Beijing, alongside collaborations with several biotech companies [4] - The company plans to invest over RMB 100 billion (approximately USD 15 billion) in China by 2030 to expand its drug production and R&D capabilities, which is expected to create thousands of new jobs [5]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [32] Core Insights - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial)," which aims to systematically reshape existing pathological pricing projects, focusing on biopsy sampling, sample processing, slice replication, pathological staining, and diagnosis, establishing 28 pricing projects, 3 additional charges, and 2 expansion items. This refined pricing is expected to promote high-quality development in pathology and create new scenarios for the application of artificial intelligence-assisted technologies [4] - The guidelines will standardize the charging for digital pathological slices, solidifying the data foundation for large-scale applications of new scenarios. It includes "providing digital images of pathological slices" as an essential item for various pathological services, reflecting the costs of related resource consumption in pricing [4] - The guidelines also explore suitable forms to respond to the charging demands of artificial intelligence assistance, promoting the early application of AI in the pathology field by including "AI-assisted diagnosis" as an expansion item in the pricing structure [4] - The establishment of separate pricing projects for pathological diagnosis and sample testing emphasizes the value of technical services and supports precise medication guidance [4] Summary by Sections Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with significant single-product potential and price revaluation prospects, such as 3SBio, Kaineng Technology, and Qianhong Pharmaceutical. Additionally, it recommends companies leading in cutting-edge technology platform layouts, such as Dongcheng Pharmaceutical, Yuanda Pharmaceutical, and Kelun-Biotech [6] - In the CXO sector, it notes that R&D investment in pharmaceuticals is steadily increasing, and the innovation environment is expected to improve, suggesting attention to companies like WuXi AppTec, WuXi Biologics, and Boteng Co. [6] - For upstream companies, it indicates that quality enterprises are entering a harvest period with overseas layouts, recommending attention to Aopumai, Baipusais, and Baiyao [6] - In the medical device sector, it mentions that ongoing procurement will continue to advance, with equipment companies gradually digesting channel inventory, suggesting attention to Mindray Medical, United Imaging, and Kaili Medical [6] Industry News - The report highlights several key developments in the industry, including Takeda's TYK2 drug achieving positive results in Phase III studies, Baiyatai's anti-VEGF monoclonal antibody application for market approval, Sanofi's innovative therapy for hypertrophic cardiomyopathy receiving domestic approval, and Enhertu (Trastuzumab Deruxtecan) gaining FDA approval for a new indication [8][12][15][16]

Core Insights - Baillie Tianheng's IPO application has been approved for a secondary listing on the Hong Kong Stock Exchange, marking a significant step in its internationalization strategy aimed at expanding global financing channels and advancing its innovative research pipeline for global clinical trials and commercialization [1][2]. Company Strategy - The company plans to conduct multiple clinical trials for its investigational drugs in the United States, pushing its core pipeline into international validation stages [1]. - Baillie Tianheng aims to establish overseas production bases through self-construction or acquisition to achieve global R&D and production synergy [1]. Key Products - Iza-bren, a dual-target antibody-drug conjugate (ADC) targeting EGFR and HER3, is highlighted as a core innovation, currently the only dual-target ADC in Phase III clinical trials globally [6][7]. - Iza-bren has a broad range of indications, including lung cancer, breast cancer, head and neck squamous cell carcinoma, and several others, with 7 indications included in the CDE's list of breakthrough therapies and 1 receiving breakthrough therapy designation from the FDA [6][7]. - T-Bren, another ADC targeting HER2, is positioned as a best-in-class candidate, with 14 clinical trials ongoing in both China and the U.S., including key registration studies [10][11][12]. Market Potential - Iza-bren is viewed as a potential challenger to the leading cancer therapy, Pembrolizumab, with a projected peak annual sales of $20 billion, and an estimated pipeline valuation ceiling of $30 billion [8][9]. - T-Bren's market strategy is informed by the success of Enhertu, a HER2 ADC developed by Daiichi Sankyo and AstraZeneca, which has seen significant sales growth [13]. Clinical Development - Baillie Tianheng is advancing multiple ADC and multi-specific antibody pipelines globally, with several candidates expected to enter early clinical trials in the U.S. by 2025 [15][16]. - The company is also exploring the potential of its HIRE-ARC platform for various tumor types, with ongoing clinical trials for candidates like BLARC001 [16].

Core Insights - AstraZeneca reported Q1 2025 revenue of $13.588 billion, a 10% year-over-year increase, driven by double-digit growth in oncology and biopharmaceuticals [1] - The company reaffirmed its full-year guidance, expecting high single-digit revenue growth and low double-digit core earnings per share growth for 2025 [1] Revenue Breakdown - In Q1 2025, AstraZeneca's revenue from the US market was $5.646 billion, a 10% increase, while revenue from China was $1.805 billion, a 5% increase, accounting for 13% of the company's global market share [1] - The oncology segment generated $5.643 billion, a 13% increase, representing 42% of total revenue, remaining the primary revenue source [2] Legal Matters - AstraZeneca is under investigation for allegedly evading import taxes exceeding $1.6 million related to the drug Enhertu, with potential fines ranging from $1 million to $8 million if found liable [1] - The company received a notice regarding alleged violations of personal information rights, asserting no illegal gains from such actions and pledging cooperation with Chinese authorities [2] Product Performance - Enhertu's global sales rose from $879 million in the previous year to $1.086 billion in Q1 2025, with a significant contribution from the Chinese market, where sales increased by 57.1% [3] - Following its inclusion in China's National Reimbursement Drug List, Enhertu has seen rapid growth in indications for HER2-positive and HER2-low expressing breast cancer [3]

4月30日，阿斯利康方面就在中国可能面临的最新罚款回应第一财经记者称："深圳海关缉私局出具 的《鉴定意见通知书》显示，公司涉嫌偷逃进口税款，金额达160余万美元。"根据相关信息，阿斯 利康认为《鉴定意见通知书》中提及的进口税款涉及德曲妥珠单抗（Enhertu）。若阿斯利康被最终 判定需承担法律责任，可能被处以未缴进口税款一至五倍的罚金，最高金额达800万美元。 ...